Monday, April 02, 2007

NY Times On WARF Patent Case

The New York Times has posted a piece by Andrew Pollack on the rulings in the WARF ESC patent case.

The story generally covers much of what you have read on the California Stem Cell Report, but also says:
"It is now much more likely, however, that the patents will be narrowed or revoked, and some scientists or companies might become more confident in undertaking research that would infringe the patents."
Pollack continues:
"Companies are charged $75,000 to $400,000, depending on their size and the terms of the license.

"The Geron Corporation, which financed some of Dr. Thomson’s research, has exclusive commercial rights to heart, nerve and pancreatic cells derived from the human embryonic stem cells. So if the patents remain in effect, any company wanting to market a treatment for heart attacks, Parkinson’s disease or diabetes using human embryonic stem cells would eventually have to come to terms with Geron. "
Sphere: Related Content

1 comment:

  1. On Friday, March 30, the USPTO mailed out first Office Actions in the re-exams of three patents assigned to WARF. These are not decisions. WARF gets an opportunity to respond to the first Office Actions.

    For more on the matter, see posts on IPBiz.